Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Restructuring (2016)

Historic Cash from Restructuring for Harvard Bioscience (HBIO) over the last 6 years, with Q3 2016 value amounting to -$27000.0.

  • Harvard Bioscience's Cash from Restructuring fell 8000.0% to -$27000.0 in Q3 2016 from the same period last year, while for Dec 2017 it was -$27000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of -$27000.0 for FY2016, which is 6823.53% up from last year.
  • As of Q3 2016, Harvard Bioscience's Cash from Restructuring stood at -$27000.0, which was down 8000.0% from -$6000.0 recorded in Q4 2015.
  • In the past 5 years, Harvard Bioscience's Cash from Restructuring ranged from a high of $95000.0 in Q3 2013 and a low of -$102000.0 during Q1 2014
  • Over the past 4 years, Harvard Bioscience's median Cash from Restructuring value was -$21000.0 (recorded in 2013), while the average stood at -$25272.7.
  • Per our database at Business Quant, Harvard Bioscience's Cash from Restructuring surged by 3043.48% in 2014 and then plummeted by 65000.0% in 2015.
  • Harvard Bioscience's Cash from Restructuring (Quarter) stood at -$97000.0 in 2013, then soared by 97.94% to -$2000.0 in 2014, then crashed by 200.0% to -$6000.0 in 2015, then plummeted by 350.0% to -$27000.0 in 2016.
  • Its Cash from Restructuring was -$27000.0 in Q3 2016, compared to -$6000.0 in Q4 2015 and -$15000.0 in Q3 2015.